![]()
|
Report Date : |
23.05.2007 |
IDENTIFICATION DETAILS
|
Name : |
MEYER- BPC JOINT VENTURE COMPANY |
|
|
|
|
Registered Office : |
No. 6A3, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2006 |
|
|
|
|
Date of Incorporation : |
2001 |
|
|
|
|
Legal Form : |
Joint Venture Company |
|
|
|
|
Line of Business : |
Manufacturing and trading pharmaceutical |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
SUBJECT
IDENTIFICATION & LEGAL FORM |
|||
|
|
|||
English Name
|
|
MEYER- BPC JOINT VENTURE COMPANY
|
|
|
Vietnamese name |
|
CONG TY LIEN
DOANH MEYER-BPC |
|
|
Trade Name |
|
MEYER –BPC CO |
|
|
Type of Business |
|
Joint venture
company |
|
|
Foundation |
|
2001 |
|
|
Investment license No |
|
2215/GP |
|
|
Date of Issuance |
|
August 20th,
2001 |
|
|
Place of Issuance |
|
Planning and
investment department of |
|
|
Invested capital |
|
1,500,000 USD |
|
|
Legal capital |
|
1,000,000 USD |
|
|
Investment duration |
|
30 years |
|
|
Tax Code |
|
1300337479 |
|
|
Total Employees |
|
230 employees |
|
|
Qualification |
|
Fairly good |
|
|
|
|||
|
|
|||
|
ADDRESS |
|||
Head Office
|
|||
|
Address |
|
No. 6A3, |
|
|
Country |
|
|
|
|
Tel |
|
(84-75) 822428 |
|
|
Fax |
|
(84-75) 817573 |
|
|
Email |
|
||
|
|
|||
|
|
|||
|
DIRECTORS |
|||
|
|
|||
|
1.
NAME |
|
Mr.
DINH VAN BICH |
|
|
Position |
|
Director |
|
|
Resident |
|
|
|
|
Nationality |
|
Vietnamese |
|
|
|
|||
|
2.
NAME |
|
Mr.
NGUYEN VAN NON |
|
|
Position |
|
Deputy Director |
|
|
Resident |
|
|
|
|
Nationality |
|
Vietnamese |
|
|
|
|||
|
3.
NAME |
|
Mr.
HUYNH THIEN NGHIA |
|
|
Position |
|
Deputy Director |
|
|
Resident |
|
|
|
|
Nationality |
|
Vietnamese |
|
|
|
|||
|
|
|||
|
BUSINESS NATURE AND
ACTIVITIES |
|||
|
|
|||
|
The subject is
specializing in manufacturing and trading pharmaceutical |
|||
|
|
|||
|
|
|||
|
IMPORT & EXPORT
ACTIVITIES |
|||
|
|
|||
|
IMPORT: The subject
imports materials and equipments from |
|||
|
EXPORT: The subject
does not export. |
|||
|
|
|||
|
|
|||
|
BANKERS |
|||
|
|
|||
|
1.
INVESMENT AND DEVELOPMENT BANK – BEN TRE BRANCH |
|||
|
Address |
|
No. 21, |
|
|
Tel |
|
84-75 829492 |
|
|
Fax |
|
84-75 824964 |
|
|
|
|||
|
|
|||
|
SHAREHOLDERS |
|||
|
|
|||
1. Name
|
|
BEN TRE PHARMACEUTICAL JOINT STOCK COMPANY
|
|
|
Address |
|
No. 6A3, |
|
|
Country |
|
|
|
|
Tel |
|
(84-75) 822429 |
|
|
Fax |
|
(84-75) 817617 |
|
Website
|
|
www.bepharco.com
|
|
|
Share |
|
60 % |
|
|
Value |
|
600,000 USD |
|
|
|
|||
2. Name
|
|
MEYER PHARMACEUTICAL LTD
|
|
Country
|
|
|
|
|
Share |
|
40 % |
|
|
Value |
|
400,000 USD |
|
|
|
|||
|
|
|||
|
PAYMENT HISTORY AND
EXPERIENCES |
|||
|
|
|||
|
Trade Morality |
|
Above average |
|
|
Liquidity |
|
|
|
|
Previous Payments |
|
|
|
|
Payment status |
|
Above average |
|
|
Past Financial Situation |
|
Average |
|
|
Current Financial Situation |
|
Fairly good |
|
|
Litigation Data |
|
No recorded |
|
|
Bankruptcy |
|
No recorded |
|
|
Public opinion |
|
Fairly good |
|
|
Payment Methods |
|
Through its bank, T.T, D.P at sight |
|
|
|
|||
|
|
|||
|
FINANCIAL DATA |
|||
|
BALANCE
SHEET |
|||
Unit: 1,000,000 VND
|
|||
|
Balance sheet
date |
31/12/2006 |
||
|
Number of weeks |
52 |
||
ASSETS
|
|||
|
A.
Working assets & short-term Investment |
26,305 |
||
|
I.
Cash and cash equivalents |
1,760 |
||
|
II.
Short-term investment |
0 |
||
|
1. Short-term securities
investment |
0 |
||
|
2. Other short-term investment |
0 |
||
|
3. Provision for short-term
investment |
0 |
||
|
III.
Receivables |
12,965 |
||
|
1. Receivables from customers |
12,250 |
||
|
2. Prepayment for providers |
288 |
||
|
3. Value-added tax deducted |
426 |
||
|
4. Internal receivables |
0 |
||
|
5. Other receivables |
1 |
||
|
6. Provision for bad
receivables |
0 |
||
|
IV. Inventory |
11,519 |
||
|
1.
Purchased goods in transit |
0 |
||
|
2. Raw materials |
11,519 |
||
|
3. Instrument, tools |
0 |
||
|
4. Cost for production and
business in process |
0 |
||
|
5. End products |
0 |
||
|
6. Goods |
0 |
||
|
7. Goods on consignment |
0 |
||
|
8. Provision for devaluation of
stocks |
0 |
||
|
V. Other current assets |
61 |
||
|
1. Advances |
0 |
||
|
2. Prepaid expenses |
61 |
||
|
3. Pending expenses for
transfer |
0 |
||
|
4. Pending assets |
0 |
||
|
5. Mortgage, collateral and
short run collateral |
0 |
||
VI.
Administrative
|
0 |
||
1. Administrative expenses for
previous year
|
0 |
||
2. Administrative expenses for
current year
|
0 |
||
|
B. Fixed assets
& Long term investment |
19,824 |
||
|
I. Fixed assets |
7,074 |
||
|
1. Tangible fixed assets |
7,074 |
||
|
+ Original cost |
9,860 |
||
|
+ Accumulated depreciation
value |
-2,786 |
||
|
2. Financial leasing fixed
assets |
0 |
||
|
+ Original cost |
0 |
||
|
+ Accumulated depreciation
value |
0 |
||
|
3. Intangible fixed assets |
0 |
||
|
+ Original cost |
0 |
||
|
+ Accumulated depreciation
value |
0 |
||
|
II. Long term
investment |
0 |
||
|
1. Long-term securities investment |
0 |
||
|
2. Joint-venture capital contribution |
0 |
||
|
3. Other long-term investment |
0 |
||
|
4. Provision for long-term investment devaluation |
0 |
||
|
III. Capital
construction in process |
12,750 |
||
|
IV. Other |
0 |
||
|
TOTAL ASSETS |
46,129 |
||
|
A.
Payable loans |
30,725 |
||
|
I. Short term
payables |
25,974 |
||
|
1. Short-term borrowings |
13,988 |
||
|
2. Due long-term liabilities |
0 |
||
|
3. Payables to supplier |
11,687 |
||
|
4. Prepayment of buyer |
0 |
||
|
5. Taxes and accounts dutiable |
0 |
||
|
6. Employee payments |
37 |
||
|
7. Internal payables |
0 |
||
|
8. Other payables |
262 |
||
|
II. Long term loans |
4,219 |
||
|
1. Long-term borrowings |
4,219 |
||
|
2. Long-term payables |
0 |
||
|
III. Other
payables |
532 |
||
|
1. Payable expenses |
532 |
||
|
2. Pending assets |
0 |
||
|
3. Receipts long-term collateral and deposit |
0 |
||
|
B. Owner’s
Equity |
15,404 |
||
|
I. Capital and Funds |
15,413 |
||
|
1. Working capital |
15,629 |
||
|
2. Differences from asset revaluation |
0 |
||
|
3. Exchange rate differences |
0 |
||
|
4. Development investment funds |
0 |
||
|
5. Reserved funds |
0 |
||
|
6. Retained profit |
-216 |
||
|
7. Construction capital sources |
0 |
||
|
II. Other administrative and fund sources |
-9 |
||
|
1. Provident funds for unemployment |
0 |
||
|
2. Reward and welfare funds |
-9 |
||
|
3. Management funds of higher level |
0 |
||
|
4. Functional operation funds |
0 |
||
|
5. Fund sources formed by fixed assets |
0 |
||
|
TOTAL LIABILITY
AND EQUITY |
46,129 |
||
|
PROFIT & LOSE
ACCOUNT (INCOME STATEMENT) |
||
|
|
||
|
Description |
F.Y 2006
|
|
|
Total
revenue |
31,083 |
|
|
Deductions Items |
499 |
|
|
- Discount |
0 |
|
|
- Devaluation |
0 |
|
|
- Return of sold goods |
499 |
|
|
- Turnover tax, Luxury tax & Export tax |
0 |
|
|
1. Net revenue |
30,584 |
|
|
2. Cost of goods sold |
30,114 |
|
|
3. Gross Profit |
470 |
|
|
4. Sales expenses |
0 |
|
|
5. |
5 |
|
|
6. Net income from business activities |
465 |
|
|
Income from financial activities |
27 |
|
|
Expenditure from financial activities |
10 |
|
|
7. Net income
from financial operation |
17 |
|
|
Irregular income |
86 |
|
|
Irregular expenditure |
5 |
|
|
8. Irregular
Profit |
81 |
|
|
9. Total pre-tax
profit |
563 |
|
|
10. Income tax |
0 |
|
|
11. After tax
profit |
563 |
|
|
|
||
|
|
||
|
FINANCIAL FACTORS |
||
|
|
||
|
Description |
F.Y 2006 |
|
|
Current Liquidity Ratio |
1.01 |
|
|
Quick Liquidity Ratio |
0.57 |
|
|
Inventory Circle |
5.23 |
|
|
Average Receive Period |
154.73 |
|
|
Utilizing Asset Performance |
0.66 |
|
|
Liability / Total Asset (%) |
66.61 |
|
|
Liability / Owner's Equity (%) |
199.46 |
|
|
Income Before Tax / Total Asset (%) ROA |
1.22 |
|
|
Income Before Tax / Owner's Equity (%) ROE |
3.65 |
|
|
Income Before Tax / Total Revenue (%) NPM |
1.81 |
|
|
Gross Profit / Total Revenue (%) GPM |
1.51 |
|
|
|
||
|
|
||
|
INTERPRETATION |
||
|
Meyer-BPC Joint Venture Company is a 60 %-40 % joint venture company between Ben Tre Pharmaceutical Joint Stock Company and Meyer Pharmaceutical Ltd. The subject got invested license No. 2215/GP on August 20th,
2001 issued by Planning and investment department of Meyer-BPC Joint Stock Company is specializing in manufacturing and trading pharmaceutical, especially non-betalactam tablet, capsule and powder tablet. After nearly two years of operation, the subject has produced
about 70 kinds of products under the GMP, GLP, and GPS standard. Currently,
the subject has four distributor branches in The subject has good business relationship with partners and is distributor of foreign firms such as Egis, Helm, AG, Cipla, Raptakos, Meyer, Gedeon Richter, Lactose New Zealand, Neo Unicap, Aceto PTE which are belonged to national such as Australia, Hungary, India, Korea, New Zealand, Germany, Thailand, China and Singapore. The subject has just been
found and operation not long time but it has prospect of development and
operation. |
||
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)